Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...

AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...

Obesity pill data released by Viking Therapeutics Inc. and AstraZeneca Plc at a big conference foreshadowed an increasingly competitive landscape for weight-loss therapies, sending down shares of ...

Novo Nordisk dropped as new data from Viking Therapeutics Inc. on an obesity pill to eventually compete with blockbuster shots spurred a rally in the small US biotech company. For more on equity ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Constellation Energy stock is lower Monday as a regulatory decision offsets the utility company's solid third-quarter ...

Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...

US stocks slumped on Monday as investors eagerly wait for the outcome of the US Presidential election on Tuesday.

After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Related Adverse Event Profile Updated Results from VENTURE Phase 2 ...

Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing better-than-expected results from a Phase 1 trial. The news sent the stock sharply ...

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...